Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China

Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China

Purpose: This study aimed to compare the clinical outcomes of camrelizumab in hepatitis B virus-related hepatocellular carcinoma (HBV–HCC) patients and non-HBV, non-HCV hepatocellular carcinoma (NBNC–HCC) patients in China.Materials and methods: A total of 54 patients with hepatocellular carcinoma w...

Full description

Bibliographic Details
Main Authors: Haonan Liu, Xiaobing Qin, Zhiyuan Xu, Meng Wu, Tong Lu, Shuang Zhou, Nan Yao, Suya Liu, Yong Shao, Zhengxiang Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Genetics
Subjects:
hepatitis B virus
hepatocellular carcinoma
immunotherapy
camrelizumab
effectiveness
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.1000448/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2022.1000448/full

Similar Items